GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
GO:00975817 | Cervix | CC | lamellipodium organization | 31/2311 | 90/18723 | 4.57e-08 | 2.76e-06 | 31 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:00975298 | Cervix | CC | myeloid leukocyte migration | 56/2311 | 220/18723 | 7.21e-08 | 4.15e-06 | 56 |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:00305957 | Cervix | CC | leukocyte chemotaxis | 57/2311 | 230/18723 | 1.48e-07 | 7.07e-06 | 57 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00300325 | Cervix | CC | lamellipodium assembly | 26/2311 | 72/18723 | 1.87e-07 | 8.48e-06 | 26 |
GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:003410110 | Cervix | CC | erythrocyte homeostasis | 37/2311 | 129/18723 | 5.16e-07 | 1.93e-05 | 37 |
GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05224 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa052241 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa04640 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
hsa046401 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0401023 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0415123 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa0522121 | Oral cavity | EOLP | Acute myeloid leukemia | 19/1218 | 67/8465 | 2.20e-03 | 7.32e-03 | 4.32e-03 | 19 |
hsa040722 | Oral cavity | EOLP | Phospholipase D signaling pathway | 31/1218 | 148/8465 | 1.82e-02 | 4.67e-02 | 2.76e-02 | 31 |
hsa0523041 | Oral cavity | EOLP | Central carbon metabolism in cancer | 17/1218 | 70/8465 | 1.87e-02 | 4.75e-02 | 2.80e-02 | 17 |
hsa0401033 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KIT | SNV | Missense_Mutation | | c.2314N>G | p.Phe772Val | p.F772V | P10721 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | | c.25N>A | p.Asp9Asn | p.D9N | P10721 | protein_coding | tolerated(0.31) | possibly_damaging(0.767) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
KIT | SNV | Missense_Mutation | novel | c.1334N>A | p.Gly445Glu | p.G445E | P10721 | protein_coding | tolerated(0.23) | probably_damaging(1) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | novel | c.1975N>A | p.Ala659Thr | p.A659T | P10721 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | rs587778433 | c.2866N>T | p.Arg956Trp | p.R956W | P10721 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
KIT | SNV | Missense_Mutation | | c.988N>G | p.Asn330Asp | p.N330D | P10721 | protein_coding | deleterious(0.02) | benign(0.01) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | novel | c.329T>G | p.Phe110Cys | p.F110C | P10721 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | novel | c.811C>T | p.Arg271Cys | p.R271C | P10721 | protein_coding | deleterious(0.04) | probably_damaging(0.982) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | novel | c.947T>C | p.Phe316Ser | p.F316S | P10721 | protein_coding | tolerated(0.81) | benign(0.003) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | rs773340705 | c.1991G>A | p.Gly664Glu | p.G664E | P10721 | protein_coding | deleterious(0) | possibly_damaging(0.455) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | Pazopanib HCl | | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178102337 | SORAFENIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | G007-LK | | 28611108 |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | Sorafenib | SORAFENIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 4'-N-BENZOYLSTAUROSPORINE | | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL124660 | TANDUTINIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178102585 | DOVITINIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178102286 | QUIZARTINIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 328083485 | OSI-930 | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | OSI-930 | OSI-930 | |